Proficio Capital Partners LLC Acquires Shares of 21,212 Exelixis, Inc. (NASDAQ:EXEL)

Proficio Capital Partners LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,212 shares of the biotechnology company's stock, valued at approximately $706,000.

A number of other institutional investors have also added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB lifted its position in shares of Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock valued at $63,000 after buying an additional 290 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock valued at $235,000 after acquiring an additional 330 shares during the period. Oregon Public Employees Retirement Fund raised its stake in Exelixis by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock valued at $1,937,000 after acquiring an additional 354 shares during the period. Principal Securities Inc. lifted its holdings in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 373 shares during the last quarter. Finally, V Square Quantitative Management LLC boosted its position in Exelixis by 37.3% during the fourth quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 425 shares during the period. 85.27% of the stock is owned by institutional investors.

Remove Ads

Analyst Ratings Changes

A number of brokerages recently commented on EXEL. Truist Financial upped their price target on shares of Exelixis from $42.00 to $43.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Bank of America downgraded Exelixis from a "buy" rating to a "neutral" rating and increased their target price for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. JMP Securities reiterated a "market outperform" rating and issued a $41.00 price target on shares of Exelixis in a research report on Thursday, January 23rd. Brookline Capital Management initiated coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a "buy" rating on the stock. Finally, Wells Fargo & Company lowered shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 price objective for the company. in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Exelixis has an average rating of "Moderate Buy" and a consensus price target of $37.59.

Exelixis Stock Down 0.3 %

NASDAQ:EXEL traded down $0.12 during midday trading on Tuesday, hitting $37.61. The company had a trading volume of 235,843 shares, compared to its average volume of 2,088,242. The company has a market capitalization of $10.52 billion, a PE ratio of 21.23, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02. The stock's fifty day moving average price is $35.66 and its 200-day moving average price is $33.00.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares in the company, valued at $11,216,403.80. This trade represents a 14.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now owns 30,406 shares of the company's stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 over the last quarter. 2.85% of the stock is owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.